Tecentriq for Locally Advanced or Metastatic Urothelial Carcinoma

News
Article

Tecentriq Product Image

Tecentriq (atezolizumab, Genetech)

Indications: Patients with locally advanced or metastatic urothelial carcinoma

  • Not eligble for cisplatin-containing chemotherapy & whose tumors express PD-L1

  • Not eligible for any platinum-containing chemotherapy regardless of PD-L1 status

  • Have disease progression during or following any platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy

Dosage

  • Metastatic Urothelial Carcinoma or Previously Treated NSCLC
  • 1200 mg intravenously 60 mins x 3weeks

  • 1200 mg IV over 60 minutes, followed by bevacizumab, paclitaxel and carboplatin, on the same day every 3 weeks x4-6

Contraindications: none

Click here for more prescribing information

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Subscribe Now!
Recent Videos
Related Content
FDA to Evaluate Merck’s Doravirine, Islatravir Regimen for HIV-1

FDA to Evaluate Merck’s Doravirine, Islatravir Regimen for HIV-1

Killian Meara
July 10th 2025
Article

The FDA set a Prescription Drug User Fee Act (PDUFA) date of April 28, 2026.

Over the Counter podcast

Episode 8: Stay in Sync with Innovations in Medication Decision Support

Drug Topics staff
August 6th 2020
Podcast

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

FDA Approves Belimumab Autoinjection for Patients 5 and Older With Active Lupus Nephritis

FDA Approves Belimumab Autoinjection for Patients 5 and Older With Active Lupus Nephritis

Ashley Gallagher
June 24th 2025
Article

This approval offers pediatric patients and caregivers the first subcutaneous option that can be administered at home.

FDA Approves Dupilumab for Treatment of Bullous Pemphigoid

FDA Approves Dupilumab for Treatment of Bullous Pemphigoid

Ashley Gallagher
June 20th 2025
Article

Bullous pemphigoid is a rare skin condition that causes large blisters filled with fluids that typically occur near skin creases, such as the upper thighs and armpits.

FDA Approves Nitisinone for Treatment of Alkaptonuria

FDA Approves Nitisinone for Treatment of Alkaptonuria

Ashley Gallagher
June 19th 2025
Article

Alkaptonuria affects approximately 1 in 250,000 to 1 million people in the United States.

FDA Approves New Moderna COVID-19 Vaccine for Older Adults, High-Risk Patients

FDA Approves New Moderna COVID-19 Vaccine for Older Adults, High-Risk Patients

Ashley Gallagher
June 2nd 2025
Article

The new approval is in line with recommendations that suggest booster vaccination for older adults and patients aged 12 to 64 with at least 1 or more underlying risk factors.

© 2025 MJH Life Sciences

All rights reserved.